SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil

PLoS Negl Trop Dis. 2022 Oct 3;16(10):e0010337. doi: 10.1371/journal.pntd.0010337. eCollection 2022 Oct.

Abstract

Background: The first case of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in Rio Grande do Norte, northeastern Brazil, was diagnosed on March 12, 2020; thereafter, multiple surges of infection occurred, similar to what was seen elsewhere. These surges were mostly due to SARS-CoV-2 mutations leading to emergence of variants of concern (VoC). The introduction of new VoCs in a population previously exposed to SARS-CoV-2 or after vaccination has been a challenge to understanding the kinetics of the protective immune response against this virus. The aim of this study was to investigate the outbreak of SARS-CoV-2 reinfections observed in mid-January 2022 in Rio Grande do Norte state, Brazil. It describes the clinical and genomic characteristics of nine cases of reinfection that occurred coincident with the introduction of the omicron variant.

Methodology/principal findings: Of a total of 172,965 individuals with upper respiratory symptoms tested for SARS-CoV-2, between March 2020 through mid-February 2022, 58,097 tested positive. Of those, 444 had documented a second SARS-CoV-2 infection and nine reinfection cases were selected for sequencing. Genomic analysis revealed that virus lineages diverged between primary infections and the reinfections, with the latter caused by the Omicron (BA.1) variant among individuals fully vaccinated against SARS-CoV-2.

Conclusions/significance: Our findings suggest that the Omicron variant is able to evade both natural and vaccine-induced immunity, since all nine cases had prior natural infection and, in addition, were fully vaccinated, emphasizing the need to develop effective blocking vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brazil / epidemiology
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Humans
  • Reinfection
  • SARS-CoV-2 / genetics
  • Viral Vaccines*

Substances

  • Viral Vaccines

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

The work was supported in part by a grant from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) to DGT, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) to SMBJ, Ministério da Saúde to DCSC, JBS to SMBJ, Ministério da Educação to SMBJ, and Ministério Público do Trabalho to SMBJ. The funders had no role in the design of the work nor the interpretation of the data.